Mechanisms of resistance to telithromycin in Streptococcus pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 3, 2005, Pages 447-450

  Hisanaga, Tamiko ^a   Hoban, Daryl J ^a,b   Zhanel, George G ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

23S rRNA; erm(B); mef(A); Mutations

Indexed keywords

BACTERIAL RNA; CETHROMYCIN; CLARITHROMYCIN; METHYLTRANSFERASE; RIBOSOME PROTEIN; RNA 23S; TELITHROMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; DELETION MUTANT; DRUG BINDING SITE; METHYLATION; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; RIBOSOME; STREPTOCOCCUS PNEUMONIAE;

BINDING SITES; DRUG RESISTANCE, BACTERIAL; KETOLIDES; MICROBIAL SENSITIVITY TESTS; MUTATION; RIBOSOMAL PROTEINS; RNA, RIBOSOMAL, 23S; STREPTOCOCCUS PNEUMONIAE;

EID: 24644522805     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki249     Document Type: Article

References (22)

1. Jedrzejas MJ. Pneumococcal virulence factors: Structure and function. Microbiol Mol Biol Rev 2001; 65: 187-207.
2. Zhanel GG, Hisanaga T, Nichol K et al. Ketolides: An emerging treatment for macrolide-resistant respiratory infections, focusing on Streptococcus pneumoniae. Expert Opin Emerg Drugs 2003; 8: 297-321.
3. Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides and streptogramin B agents: Molecular mechanisms and resistance phenotypes. Clin Infect Dis 2004; 38: S322-7.
4. Schlunzen F, Harms JM, Franceschi F et al. Structural basis for the antibiotic activity of ketolides and azalides. Structure (Cambridge) 2003; 11: 329-38.
5. Nissen P, Hansen J, Ban N et al. The structural basis of ribosome activity in peptide bond synthesis. Science 2000; 289: 920-30.
6. Capobianco JO, Cao Z, Shortridge VD et al. Studies of the novel ketolide ABT-773: Transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 1562-7.
7. Farrell DJ, Felmingham D. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003. Antimicrob Agents Chemother 2004; 48: 1882-4.
8. Canu A, Malbruny B, Coquemont M et al. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 125-31.
9. Garza-Ramos G, Xiong L, Zhong P et al. Binding site of macrolide antibiotics on the ribosome: New resistance mutation identifies a specific interaction of ketolides with rRNA. J Bacteriol 2001; 183: 6898-907.
10. Franceschi F, Kanyo Z, Sherer EC et al. Macrolide resistance from the ribosome perspective. Curr Drug Targets Infect Disord 2004; 4: 177-91.
11. Walsh F, Willcock J, Amyes S. High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae. J Antimicrob Chemother 2003; 52: 345-53.
12. Rosato A, Vicarini H, Leclercq R. Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin. J Antimicrob Chemother 1999; 43: 559-62.
13. Farrell DJ, Morrissey I, Bakker S et al. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob Agents Chemother 2004; 48: 3169-71.
14. Tait-Kamradt A, Davies T, Appelbaum PC et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44: 3395-401.
15. Perez-Trallero E, Marimon JM, Iglesias L et al. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 2003; 9: 1159-62.
16. Davies T, Dewasse B, Jacobs MR et al. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 414-7.
17. Cornaglia G, Mazzriol A, Zuliani J et al. Telithromycin activity is reduced by efflux in Streptococcus pyogenes. In: Programs and Abstracts of the 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, 2002. Abstract P473. European Society of Clinical Microbiology and Infectious Diseases.
18. Santagati M, Iannelli F, Cascone C et al. The novel conjugative transposon tn1207.3 carries the macrolide efflux gene mef(A) in Streptococcus pyogenes. Microb Drug Resist 2003; 9: 243-7.
19. Tait-Kamradt A, Reinert RR, Al-Lahham A et al. High-level ketolide-resistant streptococci. In: Programs and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract C1-1813, p. 101, American Society for Microbiology, Washington, DC, USA.
20. Novotny GW, Jakobsen L, Andersen NM et al. Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA. Antimicrob Agents Chemother 2004; 48: 3677-83.
21. Farrell DJ, Morrissey I, Bakker S et al. Mutations in erm(B) associated with rare, low-level telithromycin resistance in Streptococcus pneumoniae: 3-year data from PROTEKT. In: Programs and Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, 2004. Abstract P1465. European Society of Clinical Microbiology and Infectious Diseases.
22. Pihlajamaki M, Jalava J, Huovinen P et al. Antimicrobial resistance of invasive pneumococci in Finland in 1999-2000. Antimicrob Agents Chemother 2003; 47: 1832-5.